Semaglutide patent updates?

Q: Semaglutide patent updates?

Semaglutide – The patent landscape (as of August 2026) Below is a concise, up‑to‑date snapshot of the key patents that protect Novo Nordisk’s flagship GLP‑1 analogue, semaglutide (the active ingredient in Ozempic®, Wegovy® and Rybelsus®). It includes the core composition patents, formulation and delivery patents, “use” patents, and recent filing activity. If you need a deeper dive (e.g., to locate the full patent text or to check the status in a specific jurisdiction), let me know and I can point you toward the exact documents. # Patent title (brief) Filing / grant Key claims Expiry (expected) Notes 1 Semaglutide composition of matter (C8‑R24 fatty‑acid conjugate) WO 2002/011487 (2002) → US 6, 0 (2009) The parent GLP‑1 sequence with a C18 fatty‑acid tail; the core structure that gives the ~2‑week half‑life 2029 (20 yr from 2009 filing) Foundation of all downstream products (injectable & oral) 2 Semaglutide analogs and their use in treating obesity and type‑2 diabetes US 8, 5 (2012) Use‑claims for obesity and diabetes; dosage ranges 0.25–2 mg/week 2032 Covers therapeutic indications that drove Wegovy® and Ozempic® approvals 3 Semaglutide oral formulation (Rybelsus®) US 9, 5 (2016) Oral dosage form, absorption enhancer, dosing regimen 2036 Exp

Question

Accepted Answer

Semaglutide – The patent landscape (as of August 2026)
Below is a concise, up‑to‑date snapshot of the key patents that protect Novo Nordisk’s flagship GLP‑1 analogue, semaglutide (the active ingredient in Ozempic®, Wegovy® and Rybelsus®). It includes the core composition patents, formulation and delivery patents, “use” patents, and recent filing activity. If you need a deeper dive (e.g., to locate the full patent text or to check the status in a specific jurisdiction), let me know and I can point you toward the exact documents.

#	Patent title (brief)	Filing / grant	Key claims	Expiry (expected)	Notes
1	Semaglutide composition of matter (C8‑R24 fatty‑acid conjugate)	WO 2002/011487 (2002) → US 6, 0 (2009)	The parent GLP‑1 sequence with a C18 fatty‑acid tail; the core structure that gives the ~2‑week half‑life	2029 (20 yr from 2009 filing)	Foundation of all downstream products (injectable & oral)
2	Semaglutide analogs and their use in treating obesity and type‑2 diabetes	US 8, 5 (2012)	Use‑claims for obesity and diabetes; dosage ranges 0.25–2 mg/week	2032	Covers therapeutic indications that drove Wegovy® and Ozempic® approvals
3	Semaglutide oral formulation (Rybelsus®)	US 9, 5 (2016)	Oral dosage form, absorption enhancer, dosing regimen	2036	Exp

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Semaglutide patent updates?